Efficacy and safety of topical solution from Lactobacillus paracasei MSMC 39-1 compared to topical corticosteroid in the treatment of mild severity chronic plaque type psoriasis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250227004

Enrollment

Registered

2025-02-27

Start date

2025-01-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque type psoriasis Psoriasis, psoriasis vulgaris, plaque type psoriasis, topical postbiotic, cytokine

Interventions

Apply product on designated lesions 2 times a day, in the morning and night, 0.25 ml for 1% body surface area lesion,Apply medication on designated lesions 2 times a day, in the morning and night, 0.2

Experimental Biological/Vaccine,Active Comparator Drug

Topical solution from Lactobacillus paracasei MSMC 39-1,0.1% Triamcinolone milk lotion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with mild severity plaque type psoriasis (BSA less than 5% or PASI less than 10) and clinical stable for at least 6 months 2. The psoriatic plaques are symmetrically distributed.

Exclusion criteria

Exclusion criteria: 1. Recent application within 2 weeks of topical or intralesional corticosteroids, topical vitamin D analogs, topical calcineurin inhibitors, topical keratolytic agents, anthralin, coal tar, topical antibiotics 2. Participants recently received phototherapy on the treated areas within 4 weeks. 3. Participants recently received systemic immunosuppressants within 4 weeks or systemic medication causing inhibition of TNF-alpha, IL-12/23p40, IL-17A, IL-17R, IL-23 within 6 months. 4. Participants recently received oral probiotics within 3 months. 5. Pregnancy or lactation 6. Allergy to lidocaine

Design outcomes

Primary

Measure	Time frame
modified Psoriasis Area and Severity Index score baseline, week 4, 8, and 12 after start treatment modified Psoriasis Area and Severity Index score	—

Secondary

Measure	Time frame
Amount of Tumor Necrosis Factor-alpha, Interferon-gamma, Interleukin-12, Interleukin-17A, Interleukin-17F, and Interleukin-22 baseline and week 12 after start treatment sandwich Enzyme Linked Immunosorbent Assay,10-point visual analog scale for itching baseline, week 4, 8, and 12 after start treatment Patient reported 10-point visual analog scale,Adverse events from the treatments (erythema, burning, dryness, and scaling) baseline, week 4, 8, and 12 after start treatment Patient reported 4-point grading scale,10-point visual analog scale for overall satisfaction Week 12 after start treatment Patient reported 10-point visual analog scale	—

Measure

Time frame

Amount of Tumor Necrosis Factor-alpha, Interferon-gamma, Interleukin-12, Interleukin-17A, Interleukin-17F, and Interleukin-22 baseline and week 12 after start treatment sandwich Enzyme Linked Immunosorbent Assay,10-point visual analog scale for itching baseline, week 4, 8, and 12 after start treatment Patient reported 10-point visual analog scale,Adverse events from the treatments (erythema, burning, dryness, and scaling) baseline, week 4, 8, and 12 after start treatment Patient reported 4-point grading scale,10-point visual analog scale for overall satisfaction Week 12 after start treatment Patient reported 10-point visual analog scale

—

Countries

Thailand

Contacts

Public ContactChotinij Lertphanichkul

Faculty of Medicine, Srinakharinwirot University

chotinij@g.swu.ac.th022594260

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026